China Vaccine’s Low Efficacy Due to High-Risk Group, Says Sinovac CEO
- Sinovac’s shot was tested among high-risk medical staff
- Leading western vaccines were tested among general population
A vial of the Sinovac Biotech Covid-19 vaccine.
Source: AFP/Getty Images
This article is for subscribers only.
Chinese vaccine developer Sinovac Biotech Ltd. said that the low efficacy rate of 50.38% from its final-stage trial in Brazil is due to trial participants being medical workers facing a high risk of contracting Covid-19.
In contrast, western vaccines like that developed by Pfizer Inc. and BioNTech SE were tested among volunteers including people from the general population, some of whom were less exposed to the virus in their daily lives compared to medical workers.